The ATTC project aims to develop robust systems for the routine delivery of ATMPs as a standard of care throughout the NHS in the United Kingdom.
Over the last five years, new cell and gene therapies have been developed to treat some cancers and inherited diseases. These advanced therapies are different from existing treatments in two important ways: they are designed to restore normal function, sometimes offering cures where an unmet medical need exists and they require new ways of working by the NHS.
The ATTC network programme is a world-first, UK system of Advanced Therapy Treatment Centres (ATTC) operating within the NHS framework and coordinated by the Cell and Gene Therapy Catapult (CGT Catapult) to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients. The centres include:
- Innovate Manchester Advanced Therapy Centre Hub (iMATCH),
- Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Bristol, Cambridge, Cardiff, Leicester, Nottingham and Swansea) and
- Northern Alliance Advanced Therapies Treatment Centre (NA-ATTC, comprising Edinburgh Glasgow, Leeds and Newcastle)
The network is initially supported by the Industrial Challenge Strategy Fund delivered by UK Research and Innovation with the aim to develop first-of-a-kind technologies for the manufacture of innovative medicines across areas including blindness, cancer, heart failure, liver disease, neurological conditions and rare paediatric diseases.
As a goal of this three year project, the ATTCs are working together with industry partners and the public sector to develop the necessary processes, skilled staff and infrastructure at scale as more treatments move from clinical trial to marketed products.
The CGT Catapult is playing a central coordination role for the network and provide support to manufacturing, supply chain logistics, regulatory affairs, clinical trial capability, R&D support and upskilling via specialist training and development.
Interested in learning more about Cell and Gene Therapy?
Watch this video from NIHR
CGT Catapult team
- Jacqueline Barry, Chief Clinical Officer
- Finn Willingham, Head of ATTC Network Coordination
- Kelsie Thomas, Network Programme Manager
- Dan Baston, Network Programme Manager